Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

REMEDIAL II Results on PLC System’s RenalGuard® to be Presented at ACC 2011’s Late Breaking Clinical Trial Session

April 1, 2011 By Bio-Medicine.Org

FRANKLIN, Mass., April 1, 2011 /PRNewswire/ — PLC Systems Inc.
(OTCBB: PLCSF), a company focused on innovative medical device
technologies, today reported that final results from the REMEDIAL
II investigator-sponsored clinical trial of its RenalGuard
System™ in Italy are scheduled to be presented at 11:57 a.m.
CT on Monday, April 4, 2011, at the American College of
Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New
Orleans, Louisiana. Additionally, PLC will be demonstrating
RenalGuard at its booth (#3932) at the conference.

Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional
Cardiology, Clinica Mediterranea, Naples, Italy, and Co-Director of
Clinical Research, Laboratory of Interventional Cardiology, San
Raffaele Hospital, Milan, Italy, the principal investigator for the
REMEDIAL II trial, will present the results during a Late Breaking
Clinical Trial session at the conference.

The REMEDIAL II trial is a randomized multi-center clinical
trial in Italy designed to provide an assessment of the potential
benefits of induced diuresis with automated matched hydration
therapy utilizing RenalGuard, compared to a control group, in
reducing the incidence of Contrast Induced Nephropathy (CIN) in
patients with baseline impairment in renal function undergoing
cardiac catheterization procedures and percutaneous coronary
interventions.  

About RenalGuard®

RenalGuard is designed to reduce the potentially toxic effects
that contrast media can have on the kidneys when it is administered
to patients during certain medical imaging procedures. The
RenalGuard System consists of a proprietary console and
accompanying single-use sets.  With its automated matched
fluid replacement capability, RenalGuard is intended to promote and
maintain high urine outputs and minimize the risk to patients of
over- or under-hydration during image-guided catheterization
procedures where contrast media are rout

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech